Global law firm Clifford Chance has advised Zoetis, Inc., the world’s leading animal health company, on the acquisition of German adivo GmbH. adivo manufactures antibodies for pet medicine, especially in the fight against cancer. With its more than 1,000 m2 of lab space in Puchheim, Munich, adivo will act as one of Zoetis’ innovation hubs for antibody drug discovery.
With this acquisition, Zoetis expands its expertise in monoclonal antibodies, which have already enjoyed great success in human medicine and are also playing an increasingly important role in cancer therapy in veterinary medicine. Zoetis’ granted access to adivo’s species-specific antibody libraries and technology portfolio will drive the development of additional products and treatments tailored to the needs of veterinarians and the pets they care for.
The Clifford Chance team was led by partner Simon Schmid and comprised associate Yannick Niedergethmann, partner Christoph Holstein, associate Tobias Jenne (all Corporate), partner Claudia Milbradt, counsel Florian Reiling (both IP), partner Sebastian Ritz, senior associate Alexander Stemmler and associate Thilo Brune (all Employment, all DĂĽsseldorf), partner Olaf Mertgen and counsel Cord von Mandelsloh (Tax, Frankfurt and DĂĽsseldorf) as well as partner Dimitri Slobodenjuk and senior associate Arne Gayk (both Antitrust, DĂĽsseldorf).
